View More
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy
Alexander Drilon, MD
Released: July 10, 2020
Antitumor activity of lurbinectedin plus irinotecan in SCLC, endometrial carcinoma, and soft tissue sarcoma from ASCO 2020, as reported by Clinical care Options (CCO)
Expert commentary on the recent expanded indication for niraparib from Clinical Care Options (CCO)
Kathleen Moore, MD
Released: November 26, 2019
Multidisciplinary expert panel consisting of a physician, a nurse, and a pharmacist discuss optimal use of PARP inhibitors in ovarian cancer from various perspectives.
Laura Alwan, PharmD, BCOP
Virginia Bayer, BSN, RN, OCN
Robert L. Coleman, MD
Physicians:
maximum of 1.75 AMA PRA Category 1 Credits™
Registered Nurses:
1.7 Nursing contact hours
Pharmacists:
1.75 contact hours (0.175 CEUs)
Released: September 25, 2019
Expired: September 24, 2020
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.